EvaluatePharma (EP) projects that Pfizer Inc. (NYSE:PFE) is looking at an annual sales decline of 1% in the next five years for Prevnar 13, its bacterial pneumonia vaccine.
Why Sales May Decline
Prevnar 13 has enjoyed good momentum as one of the best-selling vaccines worldwide. This is evident in the World Preview 2016 report showing that sales in 2015 had peaked at $6.3 billion. However, EP anticipates the figure to fall to $6 billion by 2022.
Antonio Iervolino, EP Head of Forecasting, has emphasized the fact that Prevnar 13 has been significantly growing in the last five years. Consequently, a year-over-year growth becomes more and more difficult to sustain.
Aside from that, 30% of adults aged above 65 years old in the US have already been administered Prevnar 13. The vaccine has gained significant momentum in 2014 when it first became advisable for individuals aged above 65 years old.
Why Sales May Still Surge
On the other hand, Pfizer can still be hopeful for its best-selling vaccine. Prevnar 13 has just recently been awarded an approval by the US Food and Drug Administration (FDA) for individuals aged 18 to 49 years old.
Furthermore, the company’s vaccine portfolio has seen a consistent sequential growth in sales in 2015. For the full-year, the portfolio had recorded a 44% sales increase. During the first quarter, Pfizer has expressed its confidence that the full-year growth in its vaccine sales will be at par with that of the previous fiscal year (FY).
European Society for Medical Oncology (ESMO) 2016 Congress Presentation
Pfizer is slated to present data from 20 abstracts at the ESMO 2016 Congress, which is scheduled to happen on October 7 to 11.
“Pfizer looks forward to sharing news from our diverse and growing oncology portfolio, particularly in the area of novel immunotherapies and combination approaches,” noted Liz Barrett, Pfizer Oncology Global President and General Manager (GM).
Pfizer opened at $33.85 on Wednesday, rising to $33.99 at the closing bell. During the session, it had a high of $34 and a low of $33.69.